Home > Result Summaries: Compounds > Haemophilus influenzae Type b, Meningococcal C-TT Conjugate Vaccine

Result Summaries: Haemophilus influenzae Type b, Meningococcal C-TT Conjugate Vaccine

GSK Study ID	Phase	Title	Summary (Download)
102547	Phase 3	Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 mths who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec (1 citation(s))
103954	phase 3	Study to evaluate the safety,reactogenicity & immunogenicity of a booster dose of GSK Biologicals’ Hib-MenC given with Priorix™, vs Hib-MenC or Priorix™ only, in toddlers (13–14 m) primed with 3 doses of Hib (as part of a DTPa –containing vaccine) & MenC-CRM197 conjugate vaccines. (2 citation(s))
103974 (primary study)	phase 3	Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 m and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 m (3 citation(s))
104056	phase 3	Phase 3 open, controlled, multicenter, multicountry primary and booster vaccination study to demonstrate the non-inferiority of the meningoc serogroup C immune response of GSK Bios’ Hib-MenC vac co-admin with Infanrix™-IPV versus a licensed meningoc serogroup C vac co-admin with Pediacelib-MenC vac (2 citation(s))
106388	phase 3	Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC given with Infanrix™ penta versus NeisVac-C™ given with Infanrix™ hexa at 3,5m of age & persistence prior to a Hib-MenC booster at 11m & immunogenicity of the booster (2 citation(s))
106445	phase 3	Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC with Priorix™, versus MenC-CRM197 vaccine with Hiberix™ & Priorix™ in toddlers primed with Hib but not MenC & to evaluate persistence up to 5y after vaccination. (5 citation(s))
106672	phase 3	Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097 (4 citation(s))
108886	phase 4	A Phase IV, single centre, open-label study, to investigate the persistence of antibody 6 years after priming immunization with meningococcal conjugate vaccine and indiction of long term immunological memory by assessing persistence of memory B cells and response to the Hib-MenC (Menitorix) vaccine (3 citation(s))
109664	phase 4	Assessment of long-term antibody persistence after a booster dose of GSK Biologicals’ Hib & meningococcal C vaccine (Menitorix™) 811936 given at 12-15 months of age to subjects primed with 3 doses of Menitorix™ at 2, 3, 4 months of age (5 citation(s))
110215	phase 3	Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months (3 citation(s))
111709	phase 2	Study in healthy children of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine, GSK2197870A, co-administered with Prevenar™ as a three-dose primary vaccination course in infancy followed by a booster dose of Menitorix™ at 12 months of age (2 citation(s))
112830	phase 3	Persistence of antibodies after full vaccination course with GSK Biologicals’ Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age (1 citation(s))